question_id,question,ideal_answer,baseline_success,baseline_answer,togomcp_success,togomcp_answer,tools_used,baseline_recall,baseline_precision,baseline_repetition,baseline_readability,baseline_total_score,baseline_evaluation_explanation,togomcp_recall,togomcp_precision,togomcp_repetition,togomcp_readability,togomcp_total_score,togomcp_evaluation_explanation
question_001,Do both bacterial and archaeal lineages contain proteins annotated with nitrogen fixation (GO:0009399) activity?,"Yes, nitrogen fixation enzymes annotated with GO:0009399 are present in both bacterial and archaeal lineages. UniProt contains 188 distinct organisms with reviewed proteins carrying this nitrogen fixation annotation, including 14 bacterial species representing diverse phyla (Proteobacteria with Rhodobacter capsulatus and multiple Rhizobium species, Cyanobacteria with Nostoc and Trichodesmium, Firmicutes with Clostridium, and Actinobacteria) and 7 archaeal species exclusively from the methanogenic archaea group (Methanosarcina barkeri, Methanococcus maripaludis strains, Methanococcus voltae, Methanothermobacter marburgensis, Methanothermococcus thermolithotrophicus, and Methanobacterium ivanovii). This phylogenetic distribution reveals that nitrogen fixation capability evolved in bacteria and was either horizontally transferred to or independently evolved in methanogenic archaea, playing crucial roles in global nitrogen cycling across both prokaryotic domains.
",True,"Yes, both bacterial and archaeal lineages contain proteins annotated with nitrogen fixation (GO:0009399) activity. Nitrogen fixation, the process of converting atmospheric nitrogen (N₂) into ammonia, is catalyzed by the nitrogenase enzyme complex, which is found across diverse prokaryotic taxa. In Bacteria, nitrogen-fixing species are widespread and include well-studied examples such as *Rhizobium*, *Azotobacter*, *Clostridium*, and cyanobacteria like *Anabaena*. In Archaea, nitrogen fixation capability has been identified in several lineages, most notably in methanogens such as *Methanococcus* and *Methanosarcina* species, as well as in some halophilic archaea. The nitrogenase enzyme complex, consisting of the dinitrogenase reductase (encoded by *nifH*) and dinitrogenase (encoded by *nifD* and *nifK*), shows structural and functional conservation across both domains, though archaeal versions often exhibit adaptations to extreme environments. This distribution reflects the ancient origin of nitrogen fixation, likely predating the divergence of Bacteria and Archaea, and demonstrates that this metabolically crucial capability has been maintained in both prokaryotic domains throughout evolution.",True,"Based on the database query results, both bacterial and archaeal lineages contain proteins annotated with nitrogen fixation (GO:0009399) activity. The UniProt database returns numerous proteins from both domains with this functional annotation, including well-characterized bacterial nitrogen fixers such as Campylobacter jejuni, Rhizobium species, Bradyrhizobium species, Klebsiella species, and cyanobacteria like Rippkaea orientalis and Crocosphaera subtropica, as well as archaeal nitrogen fixers including multiple Methanococcus, Methanosarcina, Methanobacterium, and Methanothermococcus species, along with candidate taxa such as Candidatus Bathyarchaeota and various other Euryarchaeota members. The presence of nitrogenase-encoding genes and nitrogen fixation capability across both Bacteria and Archaea demonstrates that this metabolic function evolved early in the history of life and has been retained or horizontally transferred across diverse prokaryotic lineages inhabiting varied ecological niches from soil and aquatic environments to extreme habitats like hot springs and deep-sea sediments.","mcp__ols__fetch, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__ncbi_esearch, mcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esummary, mcp__togomcp__run_sparql",5,5,5,5,20,"The evaluated answer contains all necessary information from the ideal answer, including details about the phylogenetic distribution of nitrogen fixation enzymes across both bacterial and archaeal lineages. It also presents relevant information without unnecessary content and avoids repetition, maki",5,5,3,4,17,"The evaluated answer contains all necessary information from the ideal answer, including specific examples of organisms with nitrogen fixation annotation. However, it includes some repetition and slightly awkward phrasing, which detracts from its overall clarity and fluency."
question_002,Which human heme biosynthesis enzyme isoform lacks PDB structures?,"ALAS1 (5-aminolevulinate synthase 1, UniProt P13196) is the only human heme biosynthesis enzyme isoform that lacks PDB structures, while its erythroid-specific counterpart ALAS2 has 27 crystal structures. Heme biosynthesis proceeds through eight enzymatic steps from succinyl-CoA and glycine to heme b, with ALAS catalyzing the rate-limiting first step. The structural characterization disparity between ALAS1 (housekeeping isoform expressed ubiquitously) and ALAS2 (erythroid-specific isoform restricted to red blood cell precursors) represents a significant knowledge gap, particularly given that ALAS1 mutations cause acute intermittent porphyria while ALAS2 mutations cause X-linked sideroblastic anemia. All other pathway enzymes possess at least one solved structure: ALAD (4 structures), HMBS (11), UROS (1), UROD (19), CPOX (1), PPOX (3), and FECH (25), demonstrating that ALAS1 remains uniquely uncharacterized at the atomic level despite its regulatory importance in controlling heme synthesis rates across all tissues.
",True,"Among the human heme biosynthesis pathway enzymes, erythroid-specific 5-aminolevulinate synthase (ALAS2) is the isoform that lacks experimentally determined PDB structures. The heme biosynthesis pathway involves eight enzymatic steps, starting with two ALAS isoforms: ALAS1 (housekeeping) and ALAS2 (erythroid-specific). While ALAS1 has had its structure determined and deposited in the Protein Data Bank, ALAS2 remains structurally uncharacterized at the atomic level despite its critical role in erythroid heme synthesis. This absence is notable because ALAS2 mutations are associated with X-linked sideroblastic anemia and other hematological disorders, making structural information particularly valuable for understanding disease mechanisms and potential therapeutic interventions. The other enzymes in the pathway—including aminolevulinic acid dehydratase (ALAD), hydroxymethylbilane synthase (HMBS), uroporphyrinogen III synthase (UROS), uroporphyrinogen decarboxylase (UROD), coproporphyrinogen oxidase (CPOX), protoporphyrinogen oxidase (PPOX), and ferrochelatase (FECH)—all have available crystal structures in the PDB, making ALAS2 the primary gap in structural coverage of this essential metabolic pathway.",True,"Perfect! Now I have all the information I need. Let me provide a comprehensive answer:

Human heme biosynthesis proceeds through eight enzymatic steps catalyzed by nine enzyme isoforms, as the first enzyme, 5-aminolevulinate synthase (ALAS), exists in two tissue-specific forms: ALAS1, the housekeeping isoform expressed in all tissues, and ALAS2, the erythroid-specific isoform expressed primarily in developing red blood cells. Among these nine isoforms, ALAS1 (UniProt P13196) is the only one that lacks experimentally determined PDB structures, as confirmed by searches of the Protein Data Bank that returned no entries for this enzyme despite extensive querying. In contrast, ALAS2 (P22557) has multiple crystal structures deposited in the PDB, including 6HRH and numerous fragment-screening structures from the SGC Diamond consortium. All other enzymes in the pathway have at least one crystal structure available: ALAD (P13716) has structures such as 5HNR and 1E51, HMBS (P08397) has structures including 7AAK and 3EQ1, UROS (P10746) is represented by structure 1JR2, UROD (P06132) has numerous structures including 1URO and 1R3R, CPOX (P36551) has structure 2AEX, PPOX (P50336) has structures 3NKS and 4IVM, and FECH (P22830) has extensive structural coverage with structures such as 3HCR and 2HRE. The absence of ALAS1 structures represents a notable gap in the structural characterization of human heme biosynthesis enzymes, particularly given that ALAS1 catalyzes the rate-limiting step of the pathway in non-erythroid tissues and its expression is highly regulated by heme levels through feedback inhibition.","mcp__togomcp__search_uniprot_entity, mcp__pubmed__search_articles, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__pubmed__search_articles, mcp__pubmed__get_article_metadata, mcp__togomcp__search_uniprot_entity",4,4,3,5,16,"The evaluated answer contains most key information from the ideal answer, including the identification of ALAS2 as the erythroid-specific isoform lacking PDB structures. However, it lacks some minor details and specific context about the regulatory importance of ALAS1 in controlling heme synthesis r",5,5,5,5,20,"The evaluated answer contains all necessary information from the ideal answer, including details about ALAS1 and its lack of PDB structures. It also presents relevant information without unnecessary content and avoids repetition. The answer is well-structured, fluent, and easy to read, making it a h"
question_003,List 5 tumor suppressor proteins mentioned in 2024 cancer research publications that have both PDB structural data and drug candidates in advanced clinical development (phase ≥ 2).,"Five tumor suppressors mentioned in 2024 cancer research publications have achieved both structural characterization and therapeutic translation: TP53 (272 PDB structures, 3,621 phase≥2 drugs), MDM2 (140 structures, 3,620 drugs), BRCA1 (31 structures, 3,607 drugs), RB1 (15 structures, 12 drugs), and PTEN (11 structures, 9 drugs). All five proteins have drugs reaching marketed status (phase 4), demonstrating successful progression from structural biology to clinical therapeutics. TP53 and MDM2 show the highest therapeutic development activity with thousands of compounds, reflecting intensive efforts to target the p53-MDM2 axis in cancer. BRCA1 also shows extensive drug development, likely reflecting PARP inhibitor strategies for BRCA-deficient cancers. RB1 and PTEN have more modest drug candidate numbers but still represent validated therapeutic targets with approved treatments. This pattern reveals that major tumor suppressors with extensive structural characterization tend to have robust clinical drug development pipelines, confirming the value of structural biology in enabling rational drug design for cancer therapeutics.
",True,"I cannot provide a verified list of five tumor suppressor proteins that specifically meet all your criteria from 2024 publications. This is because accurately identifying which tumor suppressor proteins have (1) been mentioned in 2024 cancer research publications, (2) possess PDB structural data, (3) have drug candidates targeting them, and (4) those drugs are specifically in Phase 2 or later clinical trials requires access to current publication databases, clinical trial registries, and structural databases that I do not have. While several tumor suppressors like p53, PTEN, RB1, BRCA1, and BRCA2 have extensive structural characterization in the PDB and have been subjects of drug development efforts, I cannot confirm with certainty that all of these have advanced-stage drug candidates as of 2024, nor can I verify their specific mention in 2024 publications. Tumor suppressor protein drug development has historically been challenging because these proteins typically require restoration of function rather than inhibition, making traditional small-molecule approaches difficult. Some approaches like p53 reactivation compounds and PARP inhibitors (which exploit BRCA deficiencies) have reached clinical trials, but providing a definitive list of five proteins meeting your exact specifications would require verification I cannot perform.",True,"Based on my comprehensive search of 2024 cancer research publications and structural databases, I was unable to identify five tumor suppressor proteins that simultaneously meet all three criteria: (1) mentioned in 2024 cancer research publications, (2) have PDB structural data available, and (3) have drug candidates in advanced clinical development (phase 2 or higher). According to PubMed, while numerous tumor suppressor proteins were discussed in 2024 publications including BRCA1, TP53, PTEN, STK11, KEAP1, RB1, VHL, and SMARCB1, the challenge lies in identifying therapeutic agents that directly target these proteins in phase 2 or higher trials. Most tumor suppressors are inactivated by deletion or mutation in cancer, making them difficult to target pharmacologically, and current therapeutic strategies typically involve indirect approaches such as PARP inhibitors for BRCA1/2-deficient cancers ([DOI](https://doi.org/10.1001/jama.2023.25463)), MDM2 inhibitors like brigimadlin and alrizomadlin to restore p53 function in TP53-wild-type tumors ([DOI](https://doi.org/10.1158/1535-7163.MCT-23-0783), [DOI](https://doi.org/10.1016/j.esmoop.2024.103636)), CDK4/6 inhibitors that work in RB1-functional pathways, and HIF-2α inhibitor belzutifan for VHL-deficient renal cell carcinoma ([DOI](https://doi.org/10.36401/JIPO-24-13), [DOI](https://doi.org/10.1016/j.annonc.2024.08.2338)). However, these drugs target regulatory proteins or pathways affected by tumor suppressor loss rather than the tumor suppressors themselves, and comprehensive data confirming that all five meet the strict criteria simultaneously could not be established from the available 2024 literature.","mcp__pubmed__search_articles, mcp__pubmed__get_article_metadata, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_chembl_target, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_chembl_molecule, mcp__pubmed__get_article_metadata, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__togomcp__search_chembl_molecule, mcp__pubmed__get_article_metadata, mcp__pubmed__search_articles, mcp__togomcp__search_pdb_entity",2,1,3,4,10,"The answer is lacking in recall as it fails to provide a comprehensive list of tumor suppressor proteins meeting the specified criteria. It also lacks precision, containing unnecessary information and failing to verify the presence of drug candidates in Phase 2 or later clinical trials for all menti",2,4,3,4,13,
question_004,Are bacterial rhamnosyltransferase enzymes found in phyla other than Pseudomonadota and Actinomycetota?,"Bacterial rhamnosyltransferase enzymes are phylogenetically restricted to two phyla. Systematic searches of UniProt for rhamnosyltransferases (including WbbL family and EF-P arginine rhamnosyltransferases) identified enzymes exclusively in Pseudomonadota and Actinomycetota. Pseudomonadota species (E. coli, Pseudomonas, Salmonella, Neisseria, Shewanella) account for the majority of characterized enzymes, while Actinomycetota species (primarily Mycobacterium and Streptomyces) represent the second group. No rhamnosyltransferases were found in other major bacterial phyla including Firmicutes, Bacteroidetes, or Spirochaetes despite comprehensive keyword searches. This phylogenetic restriction suggests that rhamnose-based glycosylation systems evolved specifically within these two lineages and are important for their characteristic cell envelope structures—lipopolysaccharide O-antigens in Gram-negative Pseudomonadota and arabinogalactan in Actinomycetota cell walls.
",True,"Bacterial rhamnosyltransferase enzymes, which catalyze the transfer of rhamnose moieties to various acceptor molecules, are indeed found in phyla beyond Pseudomonadota (formerly Proteobacteria) and Actinomycetota (formerly Actinobacteria). These enzymes have been identified in Bacillota (formerly Firmicutes), where various Bacillus and Streptococcus species possess rhamnosyltransferases involved in cell wall polysaccharide biosynthesis and glycosylation of secondary metabolites. Bacteroidota (formerly Bacteroidetes) members also harbor rhamnosyltransferases that participate in the synthesis of complex lipopolysaccharides and capsular polysaccharides. Additionally, rhamnosyltransferases have been detected in Planctomycetota and various other less commonly studied bacterial phyla where they contribute to diverse functions including biofilm formation, virulence factor production, and biosynthesis of rhamnolipids and other rhamnose-containing glycoconjugates. The widespread distribution of these enzymes across multiple bacterial phyla reflects the fundamental importance of rhamnose-containing structures in bacterial cell surface architecture, host-microbe interactions, and specialized metabolic pathways, though Pseudomonadota remain the most extensively characterized phylum for rhamnolipid biosynthesis via rhamnosyltransferases.",True,"Perfect! Now I have comprehensive information about the bacterial phyla that contain rhamnosyltransferase enzymes. Let me compile this information into a well-formed answer.

According to PubMed, bacterial rhamnosyltransferase enzymes are indeed found in phyla beyond Pseudomonadota and Actinomycetota. Research has documented rhamnosyltransferases in Bacillota (formerly Firmicutes), including species such as Listeria monocytogenes, which possesses the RmlT wall teichoic acid rhamnosyltransferase that transfers rhamnose from dTDP-L-rhamnose to wall teichoic acids ([DOI](https://doi.org/10.1038/s41467-024-55360-1)), Bacillus licheniformis, which expresses the YjiC glycosyltransferase that functions as a rhamnosyltransferase ([DOI](https://doi.org/10.1007/s00253-019-10060-5), [DOI](https://doi.org/10.1016/j.enzmictec.2016.05.006)), and various Streptococcus species that utilize α-d-GlcNAc-β-1,4-l-rhamnosyltransferases for Group A, B, C, and G Lancefield antigen biosynthesis ([DOI](https://doi.org/10.1074/jbc.RA119.009894)). Additionally, Bacteroidota (formerly Bacteroidetes) contains rhamnosyltransferase-encoding species, including Porphyromonas gingivalis, where the GtfD protein functions as a rhamnosyltransferase essential for lipopolysaccharide synthesis ([DOI](https://doi.org/10.1111/omi.12200)). Furthermore, within Actinomycetota itself, rhamnosyltransferases extend beyond the commonly studied actinobacterial groups to include gut bacteria such as Collinsella intestinalis and Collinsella aerofaciens, which possess N-acetylglucosaminyl-diphospho-decaprenol L-rhamnosyltransferases involved in biotransformation of environmental contaminants ([DOI](https://doi.org/10.1021/acs.est.4c10434)). These findings demonstrate that rhamnosyltransferases are distributed across at least four major bacterial phyla—Pseudomonadota, Actinomycetota, Bacillota, and Bacteroidota—reflecting the widespread importance of rhamnose-containing glycoconjugates in bacterial cell surface architecture, virulence, and metabolism.","mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__pubmed__get_article_metadata, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__pubmed__get_article_metadata, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__pubmed__get_article_metadata, mcp__pubmed__search_articles, mcp__pubmed__get_article_metadata, mcp__pubmed__search_articles, mcp__pubmed__convert_article_ids, mcp__togomcp__search_uniprot_entity, mcp__pubmed__search_articles, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_uniprot_entity, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_esearch, mcp__togomcp__ncbi_efetch",5,5,5,5,20,"The evaluated answer contains all necessary information from the ideal answer, including details about the distribution of rhamnosyltransferase enzymes across various bacterial phyla. It also presents relevant and accurate information without unnecessary content or repetition, making it a clear and ",2,1,3,4,10,"The evaluated answer contains some key information about bacterial rhamnosyltransferase enzymes, but it lacks comprehensive details and fails to provide a clear, well-structured presentation. It includes unnecessary content, such as references to PubMed articles, which detract from the main message."
question_005,Which human serine/threonine kinase has the most glycosylation sites documented in Glycosmos?,"WNK1 (With No Lysine kinase 1) has the most glycosylation sites among human serine/threonine kinases, with 76 documented sites in Glycosmos - 69% more than the second-ranked kinase FAM20C (45 sites). WNK1 is a master regulator of ion homeostasis controlling renal sodium and potassium transport through phosphorylation of sodium-chloride cotransporters and potassium channels. The extensive glycosylation of WNK1 likely plays critical roles in protein folding, stability, intracellular trafficking, and protein-protein interactions necessary for its regulatory functions. Mutations in WNK1 cause Gordon's syndrome (pseudohypoaldosteronism type II), an autosomal dominant form of hypertension characterized by hyperkalemia and metabolic acidosis, underscoring the clinical importance of proper WNK1 regulation. The exceptional glycosylation extent suggests that WNK1 may be particularly vulnerable to glycosylation defects in congenital disorders of glycosylation, and that glycosylation status could represent a novel regulatory mechanism for modulating WNK1 activity in cardiovascular disease.
",True,"I don't have access to the Glycosmos database or its specific documentation of glycosylation sites for human serine/threonine kinases. Glycosmos is a specialized glycoscience database portal that integrates various glycan-related databases, and the specific ranking of which human serine/threonine kinase has the most documented glycosylation sites would require direct query access to their current data. Without access to this database or recent publications specifically citing Glycosmos data on this topic, I cannot identify which particular kinase holds this distinction. The answer would depend on the experimental validation and curation status of glycosylation sites within the Glycosmos system at any given time.",True,"Excellent! The data confirms that WNK1 (Q9H4A3) is indeed a serine/threonine-protein kinase. Based on the Glycosmos query results, I can now provide a comprehensive answer.

Serine/threonine-protein kinase WNK1 has the most glycosylation sites documented in Glycosmos among human serine/threonine kinases, with 76 distinct glycosylation sites. WNK1, also known as ""Protein kinase with no lysine 1"" or ""Kinase deficient protein,"" is encoded by the gene Q9H4A3 and functions as a serine/threonine-protein kinase with the enzyme classification EC 2.7.11.1. This extensive glycosylation pattern significantly exceeds other notable human serine/threonine kinases in the database, including extracellular serine/threonine protein kinase FAM20C with 45 sites and mitotic checkpoint serine/threonine-protein kinase BUB1 beta with 15 sites.","mcp__togomcp__run_sparql, mcp__togomcp__get_MIE_file, mcp__togomcp__run_sparql, mcp__togomcp__search_uniprot_entity",2,5,5,4,16,"The evaluated answer lacks specific information about which human serine/threonine kinase has the most glycosylation sites documented in Glycosmos, relying on external database access. However, it correctly identifies WNK1 as a master regulator of ion homeostasis and highlights its clinical importan",5,5,5,5,20,"The evaluated answer provides a comprehensive summary of WNK1, including its role as a serine/threonine-protein kinase and the extensive glycosylation pattern documented in Glycosmos. The content is accurate and well-organized, with no significant omissions or irrelevant information."
question_006,Which molybdenum-dependent enzyme has the most PDB structures?,"Nitrogenase molybdenum-iron protein has the most PDB structures among molybdenum-dependent enzymes, with 62 structures deposited for both the alpha (P07328) and beta (P07329) chains from Azotobacter vinelandii. This extensive structural characterization reflects decades of intensive research into nitrogen fixation, a process critical for converting atmospheric N₂ into bioavailable ammonia for agriculture and environmental nitrogen cycling. The molybdenum-iron cofactor (FeMo-co) at nitrogenase's active site represents one of the most complex metal clusters in biology, driving sustained structural biology efforts to understand its unprecedented chemical mechanism for breaking the remarkably stable N≡N triple bond. Other molybdenum-dependent enzymes like xanthine oxidase, aldehyde oxidase, and sulfite oxidase have significantly fewer structures, highlighting nitrogenase's exceptional importance in both fundamental biochemistry and applied agricultural science.
",True,"Xanthine oxidoreductase (XOR), which includes both xanthine oxidase and xanthine dehydrogenase forms, has the most PDB structures among molybdenum-dependent enzymes. This enzyme catalyzes the oxidation of hypoxanthine to xanthine and xanthine to uric acid in purine catabolism and contains a molybdopterin cofactor at its active site. The extensive structural characterization of xanthine oxidoreductase stems from its clinical importance as a therapeutic target for conditions including gout and hyperuricemia, leading to numerous crystal structures of the enzyme in complex with various inhibitors such as allopurinol, febuxostat, and topiroxostat. Structures have been determined from multiple species including bovine, human, and bacterial sources, with the bovine enzyme being particularly well-studied. The enzyme's relatively large size (approximately 150 kDa as a homodimer) and the presence of multiple cofactors (molybdopterin, two iron-sulfur clusters, and FAD) have made it an important model system for understanding molybdenum-dependent catalysis and electron transfer mechanisms, further driving structural studies.",True,"Let me try a different approach and check the search results I already have. Based on the PDB search results, I can see the total counts for each enzyme type. Let me verify by examining the numbers more carefully:

From the search results:
- Xanthine oxidase: 168 total structures
- Nitrate reductase: 805 total structures  
- Sulfite oxidase: 79 total structures
- DMSO reductase: 317 total structures
- Aldehyde oxidase: 544 total structures
- Formate dehydrogenase (molybdenum): 57 total structures

Based on these comprehensive search results from the PDB database, nitrate reductase has the most PDB structures among molybdenum-dependent enzymes with 805 deposited structures, significantly outnumbering other major molybdenum enzymes such as aldehyde oxidase (544 structures), DMSO reductase (317 structures), xanthine oxidase (168 structures), sulfite oxidase (79 structures), and formate dehydrogenase (57 structures). Nitrate reductases are critical enzymes in nitrogen metabolism that catalyze the reduction of nitrate to nitrite using molybdenum at their active site, and their importance in bacterial respiration, plant assimilation, and environmental nitrogen cycling has driven extensive structural characterization across multiple organisms including respiratory enzymes from Escherichia coli, Desulfovibrio species, and assimilatory enzymes from fungi and plants.","mcp__togomcp__search_uniprot_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql",4,4,3,5,16,"The evaluated answer contains most key information from the ideal answer, including the enzyme with the most PDB structures (xanthine oxidoreductase) and its clinical importance. However, it misses some important details about nitrogenase molybdenum-iron protein, such as the number of deposited stru",4,4,3,4,15,
question_007,Which ChEBI thiamine derivative is most frequently used as a cofactor in Reactome metabolic pathways?,"Thiamine(1+) (CHEBI:18385), the free cationic form of vitamin B1, is the most frequently appearing thiamine derivative in Reactome metabolic pathways with 60 occurrences, surpassing both thiamine pyrophosphate (TPP, CHEBI:58937) with 52 pathways and thiamine triphosphate (ThTP, CHEBI:9534) with 28 pathways. This counter-intuitive finding reveals that Reactome's pathway curation extensively covers thiamine transport, biosynthesis, and interconversion processes across bacterial, fungal, and plant metabolism, not merely the classic TPP-dependent enzymatic reactions like pyruvate dehydrogenase and transketolase that dominate biochemistry textbooks. The prevalence of free thiamine reflects the database's comprehensive representation of vitamin acquisition pathways, thiamine salvage mechanisms, and the multi-step phosphorylation cascade (thiamine → TMP → TPP → ThTP) that organisms use to generate the active cofactor forms, demonstrating that metabolic pathway databases capture cellular logistics of cofactor delivery alongside catalytic chemistry.
",True,"Thiamine pyrophosphate (TPP), also known as thiamine diphosphate, is the most frequently used thiamine derivative as a cofactor in Reactome metabolic pathways. TPP serves as the biologically active form of thiamine (vitamin B1) and functions as an essential cofactor for several key enzymes involved in carbohydrate metabolism and energy production. These enzymes include pyruvate dehydrogenase, which catalyzes the oxidative decarboxylation of pyruvate to acetyl-CoA in the link between glycolysis and the citric acid cycle; α-ketoglutarate dehydrogenase, which operates within the citric acid cycle itself; transketolase, which plays a critical role in the pentose phosphate pathway; and branched-chain α-ketoacid dehydrogenase, which is involved in the catabolism of branched-chain amino acids. The widespread involvement of TPP across these central metabolic pathways makes it the predominant thiamine derivative utilized in Reactome's curated biochemical reactions, far exceeding the usage of other thiamine forms such as thiamine monophosphate or free thiamine.",True,"Thiamine diphosphate (also known as thiamine pyrophosphate or TPP, with ChEBI ID CHEBI:9532) is the most frequently used thiamine derivative as a cofactor in Reactome metabolic pathways. This compound represents the active form of vitamin B₁ and serves as an essential cofactor for enzymes catalyzing critical reactions in carbohydrate and amino acid metabolism. Key metabolic pathways requiring thiamine diphosphate include the pentose phosphate pathway, where it functions as a cofactor for transketolase enzymes that catalyze carbon transfer reactions between sugar phosphates, and the citric acid cycle, where it is required by the pyruvate dehydrogenase and α-ketoglutarate dehydrogenase complexes. Additional pathways utilizing this cofactor include branched-chain amino acid catabolism, which depends on branched-chain α-ketoacid dehydrogenase activity. While other thiamine derivatives exist in biological systems, including thiamine monophosphate and thiamine triphosphate, thiamine diphosphate is uniquely positioned as the primary catalytic cofactor due to its chemical structure, which enables the formation of reactive carbanion intermediates essential for enzymatic carbon-carbon bond cleavage and formation reactions in central metabolism.","mcp__togomcp__search_chembl_molecule, mcp__ols__searchClasses, mcp__togomcp__search_reactome_entity, mcp__togomcp__run_sparql, mcp__togomcp__get_MIE_file, mcp__togomcp__search_reactome_entity, mcp__togomcp__run_sparql, mcp__togomcp__run_sparql, mcp__pubmed__search_articles, mcp__ols__fetch",4,4,3,4,15,"The evaluated answer contains most key information from the ideal answer, including the correct thiamine derivative used as a cofactor in Reactome metabolic pathways. However, it lacks specificity regarding the prevalence of free thiamine and its representation in Reactome's pathway curation, which ",4,4,3,5,16,"The evaluated answer contains most key information from the ideal answer, including the correct ChEBI ID for thiamine diphosphate and its role as a cofactor in various metabolic pathways. However, it lacks some detail about the prevalence of free thiamine in Reactome pathways and the comprehensive r"
question_008,Which 5 snake genera produce the most structurally characterized anticoagulant venom proteins?,"The five snake genera with the most structurally characterized anticoagulant venom proteins are Daboia (69 PDB structures), Bothrops (12 structures), Protobothrops (11 structures), Gloydius (6 structures), and Bungarus (5 structures). Daboia's dominance reflects the medical significance of Russell's viper envenomation across Asia and extensive structural studies of its phospholipase A2-based anticoagulants, particularly from D. russelii where a single protein (P59071) accounts for 68 structures representing different ligand complexes and functional states. The prevalence of pit viper genera (Bothrops from South America, Protobothrops and Gloydius from East Asia) in positions 2-4 demonstrates concentrated structural biology research on medically important Crotalinae venoms, while Bungarus (kraits) at position 5 shows that even primarily neurotoxic snakes possess structurally characterized anticoagulant components that contribute to the hemorrhagic syndrome of envenomation.",True,"The five snake genera that produce the most structurally characterized anticoagulant venom proteins are *Naja* (cobras), *Bungarus* (kraits), *Pseudonaja* (Australian brown snakes), *Daboia* (Russell's vipers), and *Bothrops* (lanceheads). These genera are particularly well-studied due to their medical significance and geographic distribution. *Naja* species produce numerous phospholipase A2 enzymes and three-finger toxins with anticoagulant properties that have been extensively crystallized and characterized. *Bungarus* venoms contain multiple anticoagulant phospholipase A2 isoforms and beta-bungarotoxins whose structures have been solved. *Pseudonaja* venoms are rich in prothrombin activators and factor Xa-like proteases that paradoxically cause anticoagulation through consumptive coagulopathy, with several structures deposited in protein databases. *Daboia russelii* venom contains well-characterized factor V and factor X activators, C-type lectins, and metalloproteinases that interfere with coagulation cascades. *Bothrops* species produce an extensive array of structurally characterized snake venom metalloproteinases, C-type lectins, and serine proteases that act on various coagulation factors, making this genus one of the most thoroughly investigated for venom protein structure-function relationships in the context of hemostasis disruption.",True,"Based on my comprehensive search of PubMed and the Protein Data Bank (PDB), I can now provide an answer. Let me compile the information about which snake genera have the most structurally characterized anticoagulant venom proteins.

According to PubMed and PDB database searches, the five snake genera producing the most structurally characterized anticoagulant venom proteins are Naja (cobras), Agkistrodon (copperheads and cottonmouths), Crotalus (rattlesnakes), Vipera (European vipers), and Bothrops (lance-headed vipers). Naja species possess the highest number of crystal structures, with over 33 phospholipase A2 structures deposited in the PDB, including several isoforms with documented anticoagulant activity from species like Naja naja sagittifera ([DOI](https://doi.org/10.1016/j.jsb.2009.10.010)). Agkistrodon venoms contain multiple structurally characterized anticoagulant proteins including phospholipase A2 enzymes and specialized factor X- and factor IX-binding proteins, with at least six crystal structures determined from species such as Agkistrodon contortrix contortrix ([DOI](https://doi.org/10.1074/jbc.M508502200)) and Agkistrodon acutus. Crotalus species, particularly Crotalus durissus, have yielded several crystal structures of anticoagulant phospholipase A2 isoforms within the crotoxin complex ([DOI](https://doi.org/10.3390/molecules25225290)), which exhibit both neurotoxic and anticoagulant effects through interaction with coagulation factor Xa. Vipera species, especially Vipera ammodytes ammodytes and Vipera russelli, have contributed numerous structures of ammodytoxins and other phospholipase A2 variants with anticoagulant properties ([DOI](https://doi.org/10.1107/s0907444903014987)). Bothrops venoms from species like Bothrops jararacussu contain multiple structurally characterized acidic phospholipase A2 isoforms that display significant anticoagulant activity by interfering with the coagulation cascade ([DOI](https://doi.org/10.1016/j.biochi.2003.09.011), [DOI](https://doi.org/10.1107/S0907444905029598)).","mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__pubmed__get_article_metadata, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__togomcp__search_pdb_entity, mcp__pubmed__get_article_metadata, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__togomcp__search_pdb_entity, mcp__pubmed__search_articles, mcp__pubmed__get_article_metadata, mcp__pubmed__search_articles, mcp__pubmed__get_article_metadata",4,5,3,5,17,"The evaluated answer contains most key information from the ideal answer, including all five snake genera with structurally characterized anticoagulant venom proteins. However, it lacks specific details about the number of structures deposited in protein databases for each genus and does not provide",4,2,3,4,13,
